Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. 1967

L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008433 Mathematics The deductive study of shape, quantity, and dependence. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Mathematic
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000963 Antimetabolites Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) Antimetabolite
D001377 Azaserine Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent. Azeserine,LL-D05139a,O-Diazoacetyl-L-serine,O Diazoacetyl L serine

Related Publications

L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
January 1970, Journal of the National Cancer Institute,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
February 1968, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
January 1971, Chemotherapy,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
May 1978, Journal of the National Cancer Institute,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
May 1984, Cancer research,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
September 1982, Cancer research,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
February 1967, Cancer chemotherapy reports,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
July 1988, Chemical & pharmaceutical bulletin,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
October 1979, Cancer research,
L J Wilkoff, and W S Wilcox, and J A Burdeshaw, and G J Dixon, and E A Dulmadge
January 1979, Molecular and cellular endocrinology,
Copied contents to your clipboard!